| Patents for C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397) |
|---|
| 05/26/2005 | US20050113514 Chemical synthesis of pharmaceutical agents by amidation, cyclization; chemical intermediates; solid phase synthesis |
| 05/26/2005 | US20050113450 method of sterilization, sanitation, antisepsis, and disinfection, includes applying antimicrobial compounds to a surface; e.g. 2-[(3-{[4-chloro(methyl)anilino]sulfonyl}benzoyl)amino]-5-(trifluoromethyl)benzoic acid |
| 05/26/2005 | US20050113440 Compounds that modulate PPAR activity and methods for their preparation |
| 05/26/2005 | US20050113429 E.g., 4-(2-methyl-3-oxo-hept-6-en-2-yl)-2,2-dimethyl-[1,3]-dioxane chemical intermediate; chemical/metabolic stabilization of microtubuli; antitumor, -carcinogenic agents; malignant melanoma, acute lymphocytic/myelocytic leukemia; angiogenesis inhibitors; antiinflammatory/-arthritic agents; psoriasis |
| 05/26/2005 | US20050113423 Modulators of ATP-binding cassette transporters |
| 05/26/2005 | US20050113414 1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea; potent and selective modulators of CXCR3, a chemokine receptor; antagonists; treatment of conditions involving inappropriate T-cell trafficking; antiinflammatory, -arthritic agents, autoimmune diseases; antiallergens |
| 05/26/2005 | US20050113396 Na+/H++exchanger-3 (NHE-3) inhibitors; antiischemic agents |
| 05/26/2005 | US20050113390 Treating diseases characterized by too little liquid on mucosal surfaces, applying topically on mucosal surface; increase potency, reduced mucosal absorption, and slow dissociation; long half-life on mucosal surfaces; pyrazinoylguanidine derivatives |
| 05/26/2005 | US20050113389 Sodium channel blockers |
| 05/26/2005 | US20050113388 Treating diseases characterized by too little liquid on mucosal surfaces using a"topical" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; long half-life on mucosal surfaces; pyrazinoylguanidine derivatives |
| 05/26/2005 | US20050113387 Pyrazine derivatives and pharmaceutical use thereof |
| 05/26/2005 | US20050113386 Treating bipolar disorder, mania, dementia, sexual dysfunction, eating disorders, fibromyalgia |
| 05/26/2005 | US20050113383 For therapy of allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep |
| 05/26/2005 | US20050113374 Benzodioxepine derivatives |
| 05/26/2005 | US20050113373 medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample |
| 05/26/2005 | US20050113370 Therapeutic substituted indazole derivatives |
| 05/26/2005 | US20050113369 Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| 05/26/2005 | US20050113366 Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses |
| 05/26/2005 | US20050113361 Amide derivatives as NMDA receptor antagonists |
| 05/26/2005 | US20050113360 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one |
| 05/26/2005 | US20050113359 NMDA (N-methyl-D-aspartate) receptors; eg 1-[4-(4-fluoro-benzyl)-piperidin-1-yl]-1-(6-hydroxy-1H-indole-2-yl)methanone |
| 05/26/2005 | US20050113358 Enzyme inhibitors for erectile dysfunction and sexual disorders |
| 05/26/2005 | US20050113357 Cholinergic agents such as 3-[3-(4-methoxypiperidine)-1-yl-propyl]-1H-indole; for therapy of cognitive dysfunction, forgetfulness, confusion, memory loss, attention deficits, deficits in visual perception, depression, pain, sleep disorders, and psychosis |
| 05/26/2005 | US20050113347 Novel antibacterial compounds: process for their preparation and pharmaceutical compositions containing them |
| 05/26/2005 | US20050113344 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases |
| 05/26/2005 | US20050113341 Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis |
| 05/26/2005 | US20050112781 4,7-dichlororhodamine dyes labeled polynucleotides |
| 05/26/2005 | CA2545733A1 Methods for monitoring il-18 |
| 05/26/2005 | CA2545340A1 Fused heterocyclic compounds |
| 05/26/2005 | CA2545259A1 Heteroaryl-hydrazone compounds |
| 05/26/2005 | CA2545258A1 Pyridine compounds |
| 05/26/2005 | CA2545060A1 Methods of use of thrombin receptor antagonists |
| 05/26/2005 | CA2545058A1 4-biarylyl-1-phenylazetidin-2-ones |
| 05/26/2005 | CA2544983A1 Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation |
| 05/26/2005 | CA2544693A1 Methods and compositions for selectin inhibition |
| 05/26/2005 | CA2544492A1 Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties |
| 05/26/2005 | CA2544186A1 Inhibition of fgfr3 and treatment of multiple myeloma with benzimidazole quinolinones |
| 05/26/2005 | CA2543913A1 Benzylether amine compounds useful as ccr-5 antagonists |
| 05/26/2005 | CA2541949A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| 05/25/2005 | EP1533310A1 Isonipecotamides for the treatment of integrin-mediated disorders |
| 05/25/2005 | EP1533294A1 Beta-alanine derivative and use thereof |
| 05/25/2005 | EP1532138A1 Inhibitors of tyrosine kinases |
| 05/25/2005 | EP1532132A1 Novel benzodioxoles |
| 05/25/2005 | EP1532128A1 Inhibitors of hcv ns5b polymerase |
| 05/25/2005 | EP1532122A1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| 05/25/2005 | EP1532121A1 New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives |
| 05/25/2005 | EP1532118A2 Imidazole compounds for the treatment of hepatitis c virus infections |
| 05/25/2005 | EP1532113A2 Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 05/25/2005 | EP1532111A1 2,5-disubstituted 3-mercaptopentanoic acid |
| 05/25/2005 | EP1531822A1 1-aryl-4-substituted piperazine derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders |
| 05/25/2005 | EP1531820A1 Anabaseine derivatives useful in the treatment of neurodegenerative diseases |
| 05/25/2005 | EP1531816A1 Spirocyclic piperidines as mch1 antagonists and uses thereof |
| 05/25/2005 | EP1531812A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis |
| 05/25/2005 | EP1531811A2 Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer |
| 05/25/2005 | EP1274684B1 Process for the preparation of aryl-pyridinyl compounds |
| 05/25/2005 | EP1140814B1 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| 05/25/2005 | EP1064281B1 Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor agents |
| 05/25/2005 | EP1056724B1 Substituted cycloalkyl-4-oxonicotinic carboxamides; gaba brain receptor ligands |
| 05/25/2005 | EP0946511B1 Novel compounds with analgesic effect |
| 05/25/2005 | DE10348022A1 Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen New dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases |
| 05/25/2005 | CN1620452A 3, 4-dihydro-1h-isoquinoloin-2-yl-derivatives |
| 05/25/2005 | CN1620447A Isochroman compounds for treatment of cns disorders |
| 05/25/2005 | CN1620435A 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |
| 05/25/2005 | CN1620434A Pyrrolidine-2-ones as factor Xa inhibitors |
| 05/25/2005 | CN1620296A Substituted quinazoline derivatives as inhibitors of aurora kinases |
| 05/25/2005 | CN1620294A Pyrimidine A2b selective antagonist compounds, their synthesis and use |
| 05/25/2005 | CN1203070C Thrombin receptor antagonists |
| 05/25/2005 | CN1203069C Substituted piperidines, medicaments containing these compounds, and methods for production thereof |
| 05/25/2005 | CN1203066C (Methylsulfonyl) phenyl-2-(5H)-furanones as cos-2 inhibitors |
| 05/25/2005 | CN1203060C Pyridine derivatives, its composition and use |
| 05/24/2005 | US6897886 Indolylphthalide compound and thermal recording material using the same |
| 05/24/2005 | US6897302 Reacting xylose with acetone in presence of acid catalyst; dehydration; hydrolysis; acylation in presence of basic catalyst; deblocking; halogenation |
| 05/24/2005 | US6897234 Asthma therapy; antiallergens; antiinflammatory agents |
| 05/24/2005 | US6897232 Activate soluble guanylate cyclase; for use treating cardiovascular disorders, erectile dysfunction, diabetes, and cirrhosis of the liver, kidney disorders, and learning disability |
| 05/24/2005 | US6897231 Jun n- terminal kinase inhibitors such as 3-(4-methoxyphenyl)-1H-indazole |
| 05/24/2005 | US6897230 Bicyclo[3/1/0] hexane containing oxazolidinone antibiotics and derivatives thereof |
| 05/24/2005 | US6897224 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
| 05/24/2005 | US6897219 Central nervous system diosrders; analgesics; antiinflammatory agents |
| 05/24/2005 | US6897214 Quinazoline derivatives |
| 05/24/2005 | US6897210 Anticancer agents; antiarthritic agents |
| 05/24/2005 | US6897208 Protein kinase inhibitors |
| 05/24/2005 | CA2157792C N-(3-piperidinyl-carbonyl)-beta-alanine derivatives as paf antagonists |
| 05/19/2005 | WO2005044817A1 Modulators of cellular adhesion |
| 05/19/2005 | WO2005044814A1 BENZO [b][1,4] DIOXEPINE DERIVATIVES |
| 05/19/2005 | WO2005044801A1 Pyridine carboxylic acid derivatives as glucokinase modulators |
| 05/19/2005 | WO2005044256A1 2-azetidinones as anti-hypercholesterolemic agents |
| 05/19/2005 | WO2005044192A2 Triazole compounds and uses related thereto |
| 05/19/2005 | US20050107457 Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| 05/19/2005 | US20050107432 such as 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-ylidene]methylpiperidine, used for treating nervous system, neurodegenerative and/or psychological disorders |
| 05/19/2005 | US20050107431 Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands |
| 05/19/2005 | US20050107428 Antiinflammatory agents; autoimmune diseases; rheumatic diseases; anticholesterol agents; cardiovascular disorders |
| 05/19/2005 | US20050107427 Benzyl urea and thiourea derivatives |
| 05/19/2005 | US20050107423 Quinolone antibiotics such as 1-Cyclopropyl-6-fluoro-7-(4-hydroxy-hexahydro-cyclopenta[c]pyrrol-2-yl)-8-methyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid, used for treating gramnegative or grampositive bacterial infection in mammals |
| 05/19/2005 | US20050107410 Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders |
| 05/19/2005 | US20050107406 Angiogenesis inhibitors |
| 05/19/2005 | US20050107403 Carbonylpyridine or carbonylpyrimindine compounds containing another nitrogen containing ring; useful in the treatment of inflammatory, metabolic or malignant conditions |
| 05/19/2005 | US20050107395 1-Methyl-cyclohexanecarboxylic acid {2-[4-(2-methoxy-phenyl)-piperazin-1-yl]-1-pyridin-3-ylmethyl-ethyl}-amide; used for treating a condition modulated by serotonin 5-HT1A receptors in the central nervous system and in the body of mammals |
| 05/19/2005 | US20050107388 Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain |
| 05/19/2005 | US20050107384 to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC |
| 05/19/2005 | US20050107370 Pyrrole derivatives as antimycobacterial compounds |